Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.01 from other evidence | 0.00 |
| cell type Human Protein Atlas | cell type enriched outside the brain (retinal bipolar cells) | 0.10 |
| chemistry Open Targets | reachable by antibody | 0.36 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | 5 Parkinson's papers of 138 | 0.76 |
| pathways Reactome | in no curated pathway | 0.00 |
No case: the score is under the bar. Receipt 9734
Sealed predictions
- NYX in dopamine neurons, braak+0.75 (p 0.020) → -0.28 (p 0.458)receipt 9742
Swarm cases
receipt 9742: NYX in dopamine neurons, braak
- power
- full sample +0.15 (p 0.544, n 18), 95% CI -0.34 to +0.58. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: +0.15 (p 0.549, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: +0.11 (p 0.671, n 18). could be the mix.
- skeptic
- leave-one-out range +0.05 to +0.29, sign flips 0; without severely affected donors +0.15 (p 0.544, n 18). fragile.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for NYX in dopamine neurons.
case closed: nothing better to follow up.
Receipts
loading the receipts